Defence Therapeutics Inc. Highlights ACCUM Platform for Cancer Treatments

Defence Therapeutics Inc., a Canadian biopharmaceutical company, recently featured its Chief Scientific Officer, Dr. Moutih Rafei, in an interview on Money Talk Radio with Ellis Martin. Dr. Rafei discussed the ACCUM platform, which aims to improve cancer treatments.

Based in Vancouver, Defence Therapeutics specializes in developing innovative immune-oncology vaccines and drug delivery technologies. The company’s proprietary ACCUM technology enhances precision delivery of vaccine antigens or ADCs directly to target cells, potentially increasing treatment efficacy for cancer and infectious diseases.

Listeners can access the full interview on the ABN Newswire website. Defence Therapeutics, listed on multiple stock exchanges including CSE and FSE, continues to advance in the biotechnology field with its clinical-stage developments.